Joan Albanell

9PUBLICATIONS
102CO-AUTHORS
Predictive and prognostic markersMolecular targetsCancer cell biologyInnate immunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Sep 27, 2022
Palbociclib Rechallenge for Hormone Receptor-Positive/HER-Negative Advanced Breast Cancer: Findings from the Phase II BioPER Trial.

Joan Albanell, José Manuel Pérez-García, Miguel Gil-Gil

|Sep 09, 2022
Targeted immunotherapy against distinct cancer-associated fibroblasts overcomes treatment resistance in refractory HER2+ breast tumors.

Elisa I Rivas, Jenniffer Linares, Melissa Zwick

|Jul 11, 2022
Exploring the Association of Cancer and Depression in Electronic Health Records: Combining Encoded Diagnosis and Mining Free-Text Clinical Notes.

Angela Leis, David Casadevall, Joan Albanell

|May 20, 2022
Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer.

Anna Adam-Artigues, Enrique J Arenas, Alex Martínez-Sabadell

|Mar 29, 2022
mTOR Inhibition and T-DM1 in HER2-Positive Breast Cancer.

David Casadevall, Anna Hernández-Prat, Sara García-Alonso

|Mar 18, 2022
LCOR mediates interferon-independent tumor immunogenicity and responsiveness to immune-checkpoint blockade in triple-negative breast cancer.

Iván Pérez-Núñez, Catalina Rozalén, José Ángel Palomeque

Pageof 2

Frequent Collaborators

3 joint publications

Pilar Eroles

3 joint publications

Ana Lluch

3 joint publications

David Casadevall

2 joint publications

Roger R Gomis